Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Cancer Treatment Options / Bone Marrow Transplant
Last Modified: January 22, 2006
![]()
Dear OncoLink "Ask The Experts,"
I have a friend with leukemia, and he started his second round of chemotherapy, hoping to get the remaining cancer cells. Then, after this secon0d round his doctor says he will take tests and undergo biopsy again to see if he is in remission. Our friend is going to use his own bone marrow cells rather than a donor. My question is, wouldn't a donor be better so the leukemia won't come back, rather than him using his own cells in case the chemo didn't kill some of the leukemia cells?
![]()
Carolyn Vachani RN, MSN, AOCN, OncoLink's Nurse Educator, responds:
There are pluses and minuses to both an allogeneic (donor cells) transplant and an autologous (your own cells) transplant, but not all patients have both options. In order to receive a donor's cells, you must find someone whose HLA typing is the same or very similar sometimes referred to as a match. The best donors are siblings (sisters or brothers), as they got their cellular, genetic makeup from the same parents. If siblings do not match, or a person does not have siblings, doctors will test other members of the family. If no one in the family matches (about 70% of patients do not have a family match), doctors turn to the National Marrow Donor Program (NMDP), a national organization that coordinates bone marrow donation. The NMDP registry contains 5.5 million potential donors and 40,000 units of umbilical cord blood, which can also be used. Despite these large numbers, many patients will not find a match in the NMDP registry. Those patients would then have to use their own cells. The allogeneic transplant also requires the patient to meet certain health criteria, as it has more toxicity than an autologous transplant. If a patient is too ill, autologous transplant may be their only option.
One important benefit to allogeneic transplant is that the donor's cells have a different immune system with the ability to attack any remaining cancer cells in the patient. This is called the graft versus leukemia effect. On the other hand, the donor's cells may actually attack normal cells in the patient's body because it sees these cells as foreign. This is called graft versus host disease, is undesirable, and can be very severe.
You can read more about both types of transplants in the following articles:
Dr. Vapiwala discusses the public awareness of prostate cancer and the public support for the disease. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

